PD15-01 EVALUATING 99M TC-SESTAMIBI SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY/COMPUTED TOMOGRAPHY CONCORDANCE WITH SURGICAL PATHOLOGY FOR RENAL MASSES

Abstract

You have accessJournal of UrologyCME1 May 2022PD15-01 EVALUATING 99M TC-SESTAMIBI SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY/COMPUTED TOMOGRAPHY CONCORDANCE WITH SURGICAL PATHOLOGY FOR RENAL MASSES Shilpa Argade, Carrie Ronstrom, Joel Vetter, Brijesh Patel, Mark Biebel, Joyce Mhlanga, and Robert Figenshau Shilpa ArgadeShilpa Argade More articles by this author , Carrie RonstromCarrie Ronstrom More articles by this author , Joel VetterJoel Vetter More articles by this author , Brijesh PatelBrijesh Patel More articles by this author , Mark BiebelMark Biebel More articles by this author , Joyce MhlangaJoyce Mhlanga More articles by this author , and Robert FigenshauRobert Figenshau More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002547.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Benign renal masses are challenging to differentiate from malignant renal masses using noninvasive techniques. 99m Tc-sestamibi scan single photon emission computed tomography/computed tomography (sestamibi scan) has emerged as a potential diagnostic tool. Already widely utilized in the diagnosis of hyperparathyroidism, sestamibi scans differentiate renal masses on the basis of differences in mitochondrial content between malignant renal masses and oncocytomas. This study sets out to evaluate the concordance between renal mass sestamibi scan interpretation and surgical pathology. METHODS: We retrospectively identified patients undergoing sestamibi scan and renal mass biopsy or excision between September 2016 and May 2021 at our institution. The sestamibi scan final diagnostic report and surgical pathology results were compared. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated. RESULTS: We identified 26 patients with 31 tumors. The average age of patients was 65.7 years. Sestamibi scan identified 7 oncocytomas, 20 renal cell carcinomas, and 4 mixed tumors with average size 4.8 cm, 3.2 cm, and 4.9 cm, respectively. Surgical pathology from 12 renal mass biopsies and 19 renal mass excisions showed 8 oncocytomas, 22 renal cell carcinomas, and 1 angiomyolipoma. Sestamibi scan overall accuracy was 61.3% with sensitivity 70.8%, specificity 28.6%, positive predictive value 77.3%, and negative predictive value 22.2% (Table 1). CONCLUSIONS: Previous studies have shown that as many as 20-30% of excised renal masses are benign, calling attention to the need for improved diagnostic techniques. While the overall accuracy of sestamibi scans was moderate, positive predictive value was the highest at 77.3%. This study demonstrates that sestamibi scans can be a useful noninvasive adjunct to differentiate between benign and malignant renal masses. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e262 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shilpa Argade More articles by this author Carrie Ronstrom More articles by this author Joel Vetter More articles by this author Brijesh Patel More articles by this author Mark Biebel More articles by this author Joyce Mhlanga More articles by this author Robert Figenshau More articles by this author Expand All Advertisement PDF DownloadLoading ...